Navigation Links
MD Biosciences Announces Launch of Its Onco-Immunology Suite of Preclinical Services
Date:1/27/2016

SAINT PAUL, Minn., Jan. 27, 2016 /PRNewswire/ -- MD Biosciences (http://www.mdbiosciences.com) today announced the addition of its suite of in vivo and in vitro cancer models to its family of preclinical contract research services. MD Biosciences' oncology research program specializes in murine solid tumors for subcutaneous and orthoptopic models (for example, advanced breast cancer and renal cancer) with a specific focus on the immune aspects of disease development and progression. The comprehensive services include both syngeneic and xenograft models with readouts for longitudinal tumor monitoring (for some models), longitudinal blood phenotyping (immune cell distribution, biomarkers, etc.), end time-point primary/metastatic tumor evaluation, tumor tissue-specific cellular analysis using intravascular staining (cells: epithelial, endothelial, immune etc.), biomarker analysis (blood, tumor tissue, spleen, lymph node etc.) and histological grading and evaluation of tumor specific tissue (H&E, IHC, etc.).

Logo - http://photos.prnewswire.com/prnh/20160126/326066LOGO

"Our onco-immunology research team is comprised of skilled scientists with deep-rooted expertise in a highly complex field," said Eddie Moradian, MD Biosciences CEO. "We at MD Biosciences are excited to bring our high level of expertise and our novel models to assist sponsors and partners in reaching their programs' developmental goals. This new suite of capabilities compliments our existing, best-in-class services in other disease areas."

About MD Biosciences:
MD Biosciences Preclinical Research Services is a leading provider of contract research in the core areas of inflammation, immunological, oncological, neurological and metabolic diseases. The suite of services includes a wide range of cell-based assays, in vivo disease models, translational models as well as models for the identification of the mode of action of novel drugs and compounds. The services are supported by GLP in vitro diagnostic laboratories for the testing of samples by using multiplexed genomic and proteomic methods. Proprietary models include pig models for neuropathic pain, wound healing and other key disease areas.

MD Biosciences Clinical and Diagnostics Division provides in vitro services for the testing of clinical samples. Methods include proprietary methylation assays as well as analysis of genetic markers for cancer biopsies. These methods are critical in providing personalized therapy to patients. MD Biosciences Clinical and Diagnostics Division provide analysis services for pharmaceutical clinical studies. Services include assay development, validation as well as sample acquisition, processing and reporting. All services are provided from the MD Biosciences GLP and CLIA accredited laboratories based in Saint Paul, MN.

MD Biosciences Bioproducts Division provides proprietary products for research in life sciences and specifically in drug discovery. Flagship products include highly purified collagen for the study of arthritis; ArthritoMab®, a widely used, proprietary cocktail of monoclonal antibodies for the induction of arthritis in murine studies; NeuroFreeze® kit for the preservation of harvested neuronal cells; and the newly released anti-IgD monoclonal antibody for the study of B-cell activation.

Media Contact:

Eddie Moradian, PhD
651 641 2836


'/>"/>
SOURCE MD Biosciences, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Codiak BioSciences Closes $61 Million Series B Financing
2. Kuros Biosurgery Holding Ltd. Closes Merger With Cytos Biotechnology Ltd. Which is Renamed Kuros Biosciences Ltd.
3. Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial
4. Lucerne Biosciences Completes Sourcing Investigation into Shires IPR that Led to the Invalidation of the 813 Patent
5. ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference
6. Kindred Biosciences to Provide Corporate Update
7. Sangamo BioSciences Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference
8. Imago BioSciences Announces Preclinical Data on LSD1 Inhibitor at Annual Meeting of the American Society of Hematology (ASH)
9. Cytos Biotechnology and Kuros Biosurgery to Combine to Create Kuros Biosciences
10. Neurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference
11. Representative Scott Peters Visits Avelas Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 10, 2019 , ... Thought ... with the appointment of Biofeedback Tech Ltd as its authorised distributor ... essential part of many therapeutic treatments and clinical assessment protocols to treat stress ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... human mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ cells, ... test on mice, MSC-EVs also increased the cells’ ability to lodge into bone ...
(Date:5/31/2019)... ... May 30, 2019 , ... ... pleased to announce the strategic acquisition of Metabiologics, Inc., a globally recognized leader ... Object exclusive ownership and commercialization rights to a full spectrum of botulinum neurotoxins, ...
(Date:5/15/2019)... ... May 16, 2019 , ... Emulsifiers ... result, food and beverage products rely on these ingredients to create stable quality ... label declarations. This paradigm shift triggers food formulators to seek out alternatives for ...
Breaking Biology Technology:
(Date:6/24/2019)... LOS ANGELES (PRWEB) , ... June 24, 2019 , ... ... every day with one of the four most common STDs: chlamydia, gonorrhea, trichomoniasis (or ... CDC reported that gay and bisexual African American men accounted for the largest ...
(Date:6/16/2019)... ... June 14, 2019 , ... Respected periodontist, ... the fifth annual Neodent World Congress. Attended by thousands of dental clinicians from ... advancements in the world of dentistry. The three-day event featured a team of ...
(Date:6/13/2019)... , ... June 13, 2019 , ... ... the first organization exclusively serving the end-to-end clinical and ancillary supply chain management ... as contract and medical research organizations, today announced it will sponsor a summer ...
Breaking Biology News(10 mins):